[P68] Poster Session 68　Clinical Trial Facilitation Program

[P68-9] SERENA-6: a Phase III study of AZD9833 plus CDK4/6i in HR+/HER2- mBC with detectable ESR1m before disease progression

^○Masato Takahashi¹, Francois-Clement Bidard², Kevin Kalinsky³, Massimo Cristofanilli⁴, Giampaolo Bianchini⁵, Stephen Chia⁶, Wolfgang Janni⁷, Cynthia Ma⁸, Erica Mayer⁹, Yeon Hee Park¹⁰, Steven Fox¹¹, Xiaochun Liu¹², Andrew Walding¹¹, Cynthia Huang-Bartlett¹², Nicholas Turner¹³ (1.Department of Breast Surgery, NHO Hokkaido Cancer Center, 2.Institut Curie, Paris, France, 3.Emory University, Atlanta, GA, 4.Northwestern University Feinberg School of Medicine, Chicago, IL, 5.IRCCS Ospedale San Raffaele, Milan, Italy, 6.British Columbia Cancer Agency, Vancouver, BC, Canada, 7.University Hospital Ulm, Ulm, Germany, 8.Washington University School of Medicine, St Louis, MO, 9.Dana-Farber Cancer Institute, Boston, MA, 10.Sungkyunkwan University School of Medicine, Seoul, Korea, 11.AstraZeneca, Cambridge, United Kingdom, 12.AstraZeneca, Gaithersburg, MD, 13.Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom)